Ann: Positive Overall Survival data released at ASCO 2019 Chicago, page-9

I agree @piggybanks, that gemcitabine +abraxane is a more contemporary treatment option with better OS outcomes than gemcitabine, so why then didn't OSL reference a paper looking at this chemo + radiotherapy then?

My point is, the 2011 reference chosen seems to conveniently inflate the improvement achieved in their open label trial because they've used a paper looking at the least aggressive approved chemotherapy treatment option. Their trial/s allow more then gemcitabine alone as chemotherapy, so these results at best, tell a skewed story.

I'm happy to agree to have different opinions.